Effectiveness, safety, and treatment pattern of sodium zirconium cyclosilicate in Chinese patients with hyperkalemia: interim analysis from a multicenter, prospective, real-world study (Actualize Study)
- 1The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
- 2The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
- 3Hefei First People’s Hospital, Huaihe Road, Hefei, Anhui, China
- 4Wenzhou Integrated Chinese and Western Medicine Hospital, Wenzhou, Zhejiang, China
- 5Nanyang Central Hospital, Nanyang, Henan, China
- 6Ningbo traditional Chinese Medicine Hospital, Ningbo, Zhejiang, China
- 7Taixing People’s Hospital, Taizhou, Jiangsu, China
- 8Xinghua People’s hospital, Taizhou, China
- 9Hunan Provincial People’s Hospital, Changsha, Hunan, China
- 10The First Hospital of Nanjing, Nanjing, Jiangsu, China
- 11The First Hospital of Jiaxing, Jiaxing, Zhejiang, China
- 12The First People’s Hospital of Kunshan, Suzhou, Jiangsu, China
- 13Chu Hsien-I Memorial Hospital of Tianjin Medical University, Tianjin, China
- 14Dalian Ruikaer Renal Disease Hospital, Dalian, Liaoning, China
- 15Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China
- 16Handan First Hospital, Handan, Heibei, China
- 17Linfen Central Hospital, Linfen, Shanxi, China
- 18Shanxi Provincial Hospital of Chinese Medicine, Shanxi, China
- 19Liaoning Health Industry Group Bensteel General Hospital, Benxi, Liaoning, China
- 20Nuclear Industry 416 Hospital, Chengdu, Sichuan, China
- 21Shiyan People’s Hospital, Shiyan, Hubei, China
- 22Qidong People’s Hospital Affiliated Qidong Hospital of Nantong University, Jiangsu, China
- 23Sandun District of Zhejiang Hospital, Zhejiang, China
- 24The First Affiliated Hospital of Xi’an Medical University, Xi’an, Shaanxi, China
- 25Peking University People’s Hospital, Beijing, China
- 26Taian City Central Hospital, Tai’an, Shandong, China
- 27Jiangsu Province Official Hospital, Nanjing, Jiangsu, China
- 28Changshu No. 2 People’s Hospital, Suzhou, Jiangsu, China
- 29The Affiliated Hospital of Inner Mongolia Medical University, Hohho, Inner Mongolia, China
- 30Anshan Central Hospital, Anshan, Liaoning, China
- 31Tianjin People’s Hospital, Tianjin, China
- 32Tianjin TEDA Hospital, Tianjin, China
- 33Clinical Medical College and Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China
- 34AstraZeneca Investment China Co., Medical Affairs, Shanghai, China
by Shen N, Zhang L, Yang J, Lin Y, Liu X, Cai X, Cao J, Zhu Q, Luo X, Wan X, Wu H, Ye J, Shan C, Xie H, Wu Y, Cao Y, Wang J, Yu X, Wang H, He J, Tian S, Wu F, Jiang X, Li L, Zuo L, Wang Z, Xing C, Yin X, Zhao J, MaC, Long G, Li Q, Hu Y, Shi Y and Lin H (2024). Front. Pharmacol. 15:1398953. doi: 10.3389/fphar.2024.1398953
In the published article, there was an error in Affiliation 22. Instead of “Qidong People’s Hospital, The First Hospital of Tsinghua University, Beijing, China,” it should be “Qidong People’s Hospital Affiliated Qidong Hospital of Nantong University, Jiangsu, China.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: hyperkalemia, sodium zirconium cyclosilicate, safety, real-world clinical practice, Chinese population
Citation: Shen N, Zhang L, Yang J, Lin Y, Liu X, Cai X, Cao J, Zhu Q, Luo X, Wan X, Wu H, Ye J, Shan C, Xie H, Wu Y, Cao Y, Wang J, Yu X, Wang H, He J, Tian S, Wu F, Jiang X, Li L, Zuo L, Wang Z, Xing C, Yin X, Zhao J, Ma C, Long G, Li Q, Hu Y, Shi Y and Lin H-L (2024) Corrigendum: Effectiveness, safety, and treatment pattern of sodium zirconium cyclosilicate in Chinese patients with hyperkalemia: interim analysis from a multicenter, prospective, real-world study (Actualize Study). Front. Pharmacol. 15:1495716. doi: 10.3389/fphar.2024.1495716
Received: 13 September 2024; Accepted: 16 September 2024;
Published: 01 October 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Shen, Zhang, Yang, Lin, Liu, Cai, Cao, Zhu, Luo, Wan, Wu, Ye, Shan, Xie, Wu, Cao, Wang, Yu, Wang, He, Tian, Wu, Jiang, Li, Zuo, Wang, Xing, Yin, Zhao, Ma, Long, Li, Hu, Shi and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hong-Li Lin, linhongli@vip.163.com